BioVoice News August 2017 Issue 3 Volume 2 | Page 47

and patented. At the same time, In India, doctors are still using metal screw and the children using these have to be operated upon to remove that later. It is shocking that such technology benefits are not accessed by masses. The local innovations and subsidies for mass applications could help in overcoming the shortages. If subsidies can happen in case of cancer drugs why not surgical products. a big opportunity with new dynamic set of workforce that is undergoing development currently. The researchers and new age entreprenurs have lot of opportunities based on low cost model as compared to other countries. New incubator spaces and technical support by organizations such as BIRAC is giving them confidence. I am pretty optimistic about the biotech sector in India. How do you view the biotech sector in India as an outsider? How do you look at the strengths and challenges of Indian biotech system? I think the strength of Indian biotech ecosystem is the presence of highly intellectual and skilled researchers. The big challenge is to retain them as the lack of opportunities is driving them out of the country. For example, the IIT-Mumbai’s 50 percent of students are going abroad. I don’t know if the figures are old or the things The biotech sector in India has certainly witnessed the transformation. The perception here is that the sector is are changing but the opportunities that are now being created are becoming rife. One more strength is the cost of developing the product which is much lower here as compared to manufacturing in the Europe or US. Among the challenges is the lack of funding to the research initiatives. While it is improving now but needs more attention. Also, the translational part of the product development is still a challenge. The institutions don’t have the enough expertise on intellectual property rights. The BIRAC is doing its bit on these fronts but will take time to reach the needed levels. The companies are doing the sub contracting for the tests developments of bigger global players. BIOVOICENEWS.COM 47